Maxim Group Reiterates on Sequenom Following Strong 3Q13 Results
November 08, 2013 at 11:17 AM EST
In a report published Friday, Maxim Group analyst Bryan Brokmeier reiterated a Buy rating and $6.00 price target on Sequenom (NASDAQ: SQNM ). In the report, Maxim Group noted, “We recommend that investors Buy shares of SQNM following the strong 3Q13 results. Volume was strong as sales in New York
